Healthcare Team Members Involved in Treating Myeloproliferative Neoplasms

Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.

EP: 1.A Background on Myeloproliferative Neoplasms

EP: 2.How Are Myeloproliferative Neoplasms Diagnosed?

EP: 3.Overview on the Management of Essential Thrombocythemia and Polycythemia Vera

EP: 4.Overview of Treatment Options for Myelofibrosis

Now Viewing

EP: 5.Healthcare Team Members Involved in Treating Myeloproliferative Neoplasms

EP: 6.Adverse Events Tied to Treatment for Myeloproliferative Neoplasms

EP: 7.Novel Treatment Strategies in Essential Thrombocythemia and Polycythemia Vera

EP: 8.Myelofibrosis: Novel Treatment Strategies and Combination Therapies

EP: 9.MF Progression to Acute Myeloid Leukemia and Subsequent Treatment

Related Videos

Related Content

Advertisement

December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

December 8th 2024

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

Morgan Bayer

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

November 4th 2024

Jakafi, Pegasys Combination Beneficial in Newly Diagnosed Polycythemia Vera

Alex Biese

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, research showed.

October 31st 2024

Inrebic May Reduce Spleen Volume in Myelofibrosis

Alex Biese

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.

Related Content

Advertisement

December 18th 2024

Ryoncil Receives FDA Approval for Children With GVHD

Darlene Dobkowski, MA

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

December 8th 2024

Navtemadlin Shows Biomarker Response in Patients with R/R Myelofibrosis

Morgan Bayer

Patients with relapsed or refractory (R/R) myelofibrosis experienced reduced biomarkers of disease severity following treatment with navtemadlin.

December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

November 4th 2024

Jakafi, Pegasys Combination Beneficial in Newly Diagnosed Polycythemia Vera

Alex Biese

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, research showed.

October 31st 2024

Inrebic May Reduce Spleen Volume in Myelofibrosis

Alex Biese

Second-line treatment with Inrebic has been shown to be beneficial for patients with myelofibrosis previously treated with Jakafi.